We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Prevalence and management of methotrexate-induced neurotoxicity in pediatric patients with osteosarcoma: a single-center experience.
- Authors
Peled, Yair; Levin, Dror; Shiran, Shelly; Manisterski, Michal; Shukrun, Rachel; Elhasid, Ronit
- Abstract
Aims: To determine the incidence, clinical presentation, and outcome of methotrexate (MTX) associated neurotoxicity in pediatric patients treated for osteosarcoma, with the aim of identifying possible risk factors and suggesting recommended treatment for these sequelae. Materials and methods: All medical files of patients treated for osteosarcoma in a single pediatric haemato-oncology center between November 2011 and August 2021 were retrospectively reviewed. All patients were treated according to the EURAMOS AOST0331 protocol, using cisplatin, doxorubicin, and high-dose MTX at a dose of 12 g/m2 over 4 h. Results: Seventy-eight patients with osteosarcoma were identified (age range 5 to 23 years, 42 males). Seven patients (9%) sustained neurotoxicity following treatment with high-dose MTX. Manifestations of neurotoxicity included among others, generalized seizures, confusion, encephalopathy, dysarthria, and choreiform movements. All but one episode occurred following two sequential cycles of high-dose MTX. All 7 had subacute toxicity, 5–10 days following MTX administration, and 1 had both acute and subacute toxicity. Brain MRI was performed for all patients and demonstrated typical MRI changes attributed to MTX neurotoxicity in 4 of them. Two patients received aminophylline; one patient received dextromethorphan. Patients with normal MRI imaging resumed MTX therapy without any sequels. No risk factors were found for high-dose MTX-related toxicity occurrence. Conclusions: The time of risk of neurotoxicity due to high-dose MTX treatment for osteosarcoma is days 5–10 following two sequential treatment cycles. These findings together with treatment options for these adverse effects should be detailed in the therapeutic protocol of MTX use among pediatric patients with osteosarcoma.
- Subjects
CHILD patients; OSTEOSARCOMA; NEUROTOXICOLOGY; MAGNETIC resonance imaging; SYMPTOMS
- Publication
International Journal of Clinical Oncology, 2022, Vol 27, Issue 8, p1372
- ISSN
1341-9625
- Publication type
Article
- DOI
10.1007/s10147-022-02184-y